ProMIS Neurosciences, Inc. (PMN) 

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Show less

Over the last 12 months, insiders at ProMIS Neurosciences, Inc. have bought $0 and sold $0 worth of ProMIS Neurosciences, Inc. stock.

On average, over the past 5 years, insiders at ProMIS Neurosciences, Inc. have bought $44,411 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 150,000 shares for transaction amount of $0 was made by Sclar Jeremy M. (10 percent owner) on 2023‑12‑04.